取Witepsol H-15(19.5～49.5 g)及蔗糖脂肪酸酯(SE)(0～30 g)放入烧杯中,置90℃油浴中熔融,然后加入消炎痛(IM)(0.5 g)溶解或混悬于基质,冷却至60℃,倾入栓模(1 ml容积),迅速放冰箱冷至5℃。随着SE含量的增加,栓剂的软化点也增高。用Muranishi法测体外释放,表明SE含量超过52.5%时得到缓释曲线,不含SE或含20%、30%SE的栓剂在1小时已释放40～50%,此时含52.5%SE的栓剂仅释放20%,至5小时才释放50%,含SE60%的栓剂1小时仅释放5%,5小时也仅释放20%。体内吸收试验用雄性兔,体重2.8～ Place Witepsol H-15 (19.5-49.5 g) and sucrose fatty acid ester (SE) (0-30 g) in a beaker, melt in a 90 ° C oil bath and dissolve with indomethacin (0.5 g) Or suspended in the matrix, cooled to 60 ℃, poured into the plug mode (1 ml volume), the refrigerator quickly cooled to 5 ℃. As the SE content increases, suppository softening point also increased. The in vitro release was measured by the Muranishi method, which showed that a sustained release curve was obtained with a SE content greater than 52.5%. The suppositories without SE or with 20%, 30% SE were released 40-50% at 1 hour, at which time a suppository containing 52.5% SE Only released 20% to 50 hours to release 50%, SE60% suppositories released only 5% 1 hour 5 hours also released only 20%. In vivo absorption test male rabbits, weighing 2.8 ~